Auriga

We have come to recognize analyst ratings are a special breed of financial news that can yield profitable trading signals when caught early and approached the right way. They do go awry often, but when they work, they can produce some spectacular returns. Below are ten analyst calls made in 2012,...

Auriga raises its price target $2 to $19 on Hold-rated Worthington Industries (NYSE: WOR) as the company modestly exceeds F3Q EPS expectations. Auriga says, "Worthington Industries (WOR) reported fiscal 3Q12 EPS of $0.37 versus our estimate of $0.35 and consensus of $0.35 (range: $0.26 - $0.38...

Auriga raises its price target to $135 on Buy-rated TransDigm (NYSE: TDG) on revised estimated reflecting traffic and capacity trend strength. Auriga says, "We are increasing our price target on shares of TDG to $135, from $130, which reflects continued strength in traffic and capacity trends,...

In a research report released this morning by Auriga, Affymax (NASDAQ: AFFY) announced the FDA approval of Peginesatide, an anemia treatment for adult patients with chronic kidney disease. According to Auriga, “First pass approval is in line with our expectations and appears to have been...

According to a research report published this morning, Auriga has raised Steve Madden's (NASDAQ: SHOO) Q1 EPS estimate by $0.01 to $0.50. Auriga commented in the report, “We are increasing our Q1 EPS estimate following channel checks that point to strong sell through and limited discounting of...

Auriga lowers its price target from $89 to $88 on Hold-rated Weight Watchers International (NYSE: WTW) on adjusted share count following completion of Dutch tender near top end of its price range. Auriga says, "Weight Watchers completed its Dutch tender Thursday evening, repurchasing over 18...

Auriga increases its price target to $22 on Hold-rated AAR Corporation (NYSE: AIR) on margin pressure that offset stronger outlook on revenue. Auriga says, "AAR reported third-quarter operating results behind expectations, although headline EPS of $0.50 came in $0.02 ahead of consensus on a $0.09...

Auriga raises its price target to $128 on Buy-rated Nike (NYSE: NKE) ahead of FQ3. Auriga says, "We are increasing our estimates on NKE for the quarter and year to reflect our belief that NKE's superior product offering could lead to continued earnings growth going forward. We expect sales +15%...

Auriga raises its price target $1.50 to $8 on Hold-rated PMC-Sierra (NASDAQ: PMCS) on opex restraint and share buyback. Auriga notes, "Overall, we are encouraged by management's commitment to opex restraint and stock buybacks and also see much lower headwinds from legacy segments. However, we are...

According to a research report released earlier today, Auriga has downgraded Anthera Pharmaceuticals Inc. (NASDAQ: ANTH) from Hold to Sell based on excessive valuation. Auriga commented in the report, “We also note interesting competition from upstart CareCloud (private) which boasts a more...

According to a recent research report published by Auriga, Affymax Inc.'s (NASDAQ: AFFY) reported 4Q11 revenue/EPS, with earnings still not becoming a major driver for the company. In the report, Auriga said, “AFFY provided 2012 expense guidance, but will not provide product revenue guidance at...

In a research report published today by Auriga, Healthcare Management Associates (NYSE: HMA) saw significantly lower flu activity in 1Q11, along with a drop it unemployment. According to Auriga, “Channel checks indicate orthopedic surgeries are growing, while cardiac cases are flat in HMA markets...

Auriga reduces its price target $5 to $21 on Buy-rated Medifast (NYSE: MED) on persisting growing pains. Auriga says, "Medifast announced 4Q11 results and 1Q12 guidance that was below our expectations, partially due to margin pressure associated with startup costs in its Weight Control Center...

Auriga increases its price target to $86 on Lululemon Athletica (NASDAQ: LULU) as the company is expected to provide a solid guidance for 2012. Auriga says, "We expect LULU to report Q4 EPS of $0.49, the high end of the company's upward preannounced range. We believe all eyes are on 2012 and...

Auriga increases its price target to $65 on Buy-rated DSW (NYSE: DSW) on expectations that 2012 will be a year of growth. Auriga notes, "We believe DSW is poised to report a strong Q4 and provide a bullish outlook for 2012. We believe the warm start to spring could have generated consumer...